Back to top
more

Myriad Genetics, Inc. (MYGN)

(Delayed Data from NSDQ)

$25.41 USD

25.41
842,189

-1.01 (-3.82%)

Updated Jun 27, 2017 04:00 PM ET

Add to portfolio

3-Hold     3    

B Value | D Growth | A Momentum | B VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There\'s also a VGM Score (\'V\' for Value, \'G\' for Growth and \'M\' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 25.71%
2 Buy 18.12%
3 Hold 9.91%
4 Sell 5.49%
5 Strong Sell 2.29%
S&P 500 9.79%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for MYGN

   

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for Myriad Genetics, Inc. falls in the month of June.

All items in Millions except Per Share data.

6/30/2016 6/30/2015 6/30/2014 6/30/2013 6/30/2012
Assets          
Cash & Equivalents 159 145 186 372 341
Receivables 95 88 85 98 63
Notes Receivable 0 0 0 0 0
Inventories 38 25 24 5 12
Other Current Assets 22 26 27 9 7
Total Current Assets 315 284 322 484 422
Net Property & Equipment 58 67 35 28 24
Investments & Advances 80 41 84 159 114
Other Non-Current Assets 0 0 0 22 19
Deferred Charges 0 0 3 29 31
Intangibles 423 370 374 70 73
Deposits & Other Assets 5 5 5 13 8
Total Assets 881 766 824 804 691
Liabilities & Shareholders Equity 6/30/2016 6/30/2015 6/30/2014 6/30/2013 6/30/2012
Notes Payable 0 0 0 0 0
Accounts Payable 21 21 23 18 10
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 50 46 56 44 33
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 2 2 1 2 2
Total Current Liabilities 72 69 81 65 45
Mortgages 0 0 0 0 0
Deferred Taxes/Income 18 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 42 35 24 11 10
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 132 104 105 75 55
Shareholders Equity 6/30/2016 6/30/2015 6/30/2014 6/30/2013 6/30/2012
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 830 745 718 697 648
Retained Earnings -73 -77 2 31 -13
Other Equity -10 -7 -2 -0 -0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 748 662 719 729 636
Total Liabilities & Shareholder's Equity 881 766 824 804 691
Total Common Equity 748 662 719 729 636
Shares Outstanding 70.30 69.40 74.80 79.60 84.80
Book Value Per Share 10.64 9.54 9.61 9.15 7.50

Fiscal Year End for Myriad Genetics, Inc. falls in the month of June.

All items in Millions except Per Share data.

3/31/2017 12/31/2016 9/30/2016 6/30/2016 3/31/2016
Assets          
Cash & Equivalents 172 163 148 159 217
Receivables 119 112 103 95 94
Notes Receivable 0 0 0 0 0
Inventories 47 51 54 38 25
Other Current Assets 10 16 18 22 36
Total Current Assets 348 342 323 315 372
Net Property & Equipment 53 55 57 58 60
Investments & Advances 53 56 52 80 70
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 813 822 834 423 361
Deposits & Other Assets 0 3 5 5 5
Total Assets 1,268 1,276 1,271 881 868
Liabilities & Shareholders Equity 3/31/2017 12/31/2016 9/30/2016 6/30/2016 3/31/2016
Notes Payable 0 0 199 0 0
Accounts Payable 27 23 20 21 14
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 64 58 55 50 51
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 131 2 1 2 2
Total Current Liabilities 222 83 275 72 66
Mortgages 0 0 0 0 0
Deferred Taxes/Income 85 86 88 18 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 167 204 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 46 173 42 32
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 520 543 536 132 98
Shareholders Equity 3/31/2017 12/31/2016 9/30/2016 6/30/2016 3/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 840 832 827 830 847
Retained Earnings -81 -86 -87 -73 -69
Other Equity -11 -14 -6 -10 -8
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 748 733 735 748 770
Total Liabilities & Shareholder's Equity 1,268 1,276 1,271 881 868
Total Common Equity 748 733 735 748 770
Shares Outstanding 68.00 68.40 68.70 70.30 71.20
Book Value Per Share 11.00 10.71 10.70 10.64 10.82